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Objective: To explore the non-pharmacological correlates of the
perceived eﬀectiveness of antidepressants (ADs), thereby enhancing
understanding of the mechanisms involved in recovery from depression
while taking ADs.
Method: An online survey was completed by 1781 New Zealand adults
who had taken ADs in the previous 5 years.
Results: All 18 psychosocial variables measured were associated with
depression reduction, and 16 with improved quality of life (QoL).
Logistic regression models revealed that the quality of the relationship
with the prescriber was related to both depression reduction and
improved QoL. In addition, depression reduction was related to
younger age, higher income, being fully informed about ADs by the
prescriber, fewer social causal beliefs for depression and not having lost
a loved one in the 2 months prior to prescription. Furthermore, both
outcome measures were positively related to belief in ‘chemical’ rather
than ‘placebo’ eﬀects.
Conclusion: There are multiple non-pharmacological processes involved
in recovery while taking ADs. Enhancing them, for example focusing
on the prescriber–patient relationship and giving more information,
may enhance recovery rates, with or without ADs.
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Signiﬁcant outcomes
• Self-reported positive outcomes while taking antidepressants are related to multiple psychosocial
variables.
• Patient characteristics, including demographics and causal beliefs, are related to whether antidepres-
sants are perceived to have worked.
• The patient–prescriber relationship, including amount of information imparted, is an important pre-
dictor of outcome when taking antidepressants.
Limitations
• Older people, poorer people and ethnic minorities were under-represented in the convenience sample.
• The data relied on self-report.
• The causal direction of some of the correlational ﬁndings is ambiguous.
Introduction
By 2005, one in 10 people over the age of six in the
USA were being prescribed antidepressants (ADs)
annually (1). In England, prescriptions for ADs
increased 10% per year between 1998 and 2010 (2).
In New Zealand, where the current study was con-
ducted, the number of annual prescriptions rose by
The copyright line for this article was changed on 9 September 2015 after original online publication.
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37% between 2006/07 and 2011/12, from
1 007 109 to 1 385 133; while the number of recip-
ients per year increased by 35% from 304 530 to
412 631 (PHARMAC, personal communication,
2012), in a population of 4.4 million, of whom 3.7
million are aged 16 or older. Thus, one in nine of
the adult population (and approximately one in six
women) are now prescribed ADs every year. These
dramatic increases in prescribing rates are occur-
ring in the context of stable prevalence rates of
depression and high rates of prescribing to people
who do not meet diagnostic criteria for a depres-
sive ‘disorder’ (3). Another contextual factor is the
pervasive inﬂuence of the pharmaceutical industry,
not least in terms of their funding of mental health
internet websites which espouse simplistic bio-
genetic causal explanations and promote their
products (4, 5).
Recent research has raised concerns about the
eﬃcacy of ADs, compared with psychological
treatments or placebo; with placebo response rates
of around 50% being found (6–8). Less than half
of drug trials ﬁnd ADs superior to placebo (8). A
meta-analysis (9), which included previously
unpublished drug company studies, found that ‘the
overall eﬀect of new-generation AD medications is
below recommended criteria for clinical signiﬁ-
cance’ (p. 265) with no signiﬁcant beneﬁt com-
pared with placebo for all but ‘patients at the
upper end of the very severely depressed category’
(p. 260).
The non-speciﬁc eﬀects of a treatment are clearly
an important ingredient of why ADs, and other
treatments, work. Depression has been found to be
highly sensitive to such eﬀects (10). These eﬀects
are persistent not transient (11) and have demon-
strable neural correlates (12). A recent review of
AD drug trials categorised the factors that can
inﬂuence non-speciﬁc, or non-pharmacological
eﬀects into ﬁve domains: healthcare environment,
practitioner characteristics, patient characteristics,
practitioner–patient interaction and non-pharma-
ceutical drug characteristics (7). The focus of this
particular review was the infrequency with which
most of these factors are recorded in drug trials,
thereby limiting the ability of the trials to accu-
rately assess the pharmacological eﬀect of ADs.
For example, none of the 82 studies recorded either
the beliefs or expectations of the patients, and – in
the practitioner–patient domain – only 2%
recorded levels of empathy or congruence. Besides
enhancing the validity of drug trials, an equally
compelling reason for studying these variables is
that by understanding the psychosocial factors
that are related to perceived positive outcomes
while taking ADs we may be better able to identify
and enhance those factors which lead to better out-
comes, with or without ADs.
Aims of the study
The current study, therefore, reports the ﬁndings
from an online questionnaire completed by antide-
pressant users, with a primary focus on patient
characteristics (demographics and beliefs) and
practitioner–patient interactions (quality of rela-
tionship and information conveyed). The associa-
tions between these various factors and two
measures of perceived eﬀectiveness, reduced depres-
sion and improved quality of life, are reported.
Material and methods
Instrument
The questionnaire had 47 questions (in either yes/
no, likert scale, or open-ended formats), in eight
sections: demographics; the prescribing process;
information about AD usage and perceptions of
their eﬀectiveness; side-eﬀects; beneﬁts; experiences
of alternative treatment options; and beliefs about
the causes of depression. The criteria for participa-
tion included having been prescribed ADs in the
last 5 years and being 18 years of age or over.
Recruitment
The study was approved by the University of
Auckland Human Participants Ethics Committee.
The anonymous questionnaire was placed online
using a survey website that guarantees the protec-
tion of data. A Google web page advertising
the study (www.viewsonantidepressants.co.nz)
provided the participant information for the study
and a link to the online questionnaire. The study
was further publicised in the New Zealand media
via media releases, interviews with the researchers
and advertisements.
Participants
Of the 2171 people who started the survey, 295
stopped before the end of the second section (ques-
tion 19 of 47) and their responses were not analy-
sed. Of the remaining 1876, 45 cited medications
other than ADs in response to questions about
which AD they had been prescribed. The Internet
Protocol address (IP) of 168 of the remaining 1831,
was the same as at least one other respondent, indi-
cating possible use of the same computer (although
several devices can share IP addresses). The
responses of these 168 were checked, and two
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respondents whose scores were nearly identical to
those of someone else with the same IP were
excluded. This left 1829. A further 48 who had
been prescribed ADs but had not taken them were
excluded, leaving 1781 for analysis. The number of
responses to each question varied as not all partici-
pants responded to all questions.
Data analysis
Two outcomes were measured in the study:
i) Perceived reduction in depression – (‘Yes’ or
‘No’ in response to ‘Did the antidepressant
reduce your depression?’)
ii) Perceived improvement in quality of life
(QoL) – (‘greatly improved’, ‘slightly
improved’, ‘unchanged’, ‘slightly worse’ or ‘a
lot worse’ – in response to ‘While taking an-
tidepressants my quality of life was . . .’).
It was hypothesised that a range of 18 psychoso-
cial factors may be associated with these two out-
comes. These potential explanatory factors (see
Table 1) included sociodemographic attributes,
information received from the prescribing doctor,
perceived relationship with the doctor and beliefs
about the causes of their own depression, about
the eﬃcacy of ADs and about ‘chemical’ vs.
Table 1. Descriptive data for the 20 variables used in the analyses
N % N %
Gender ‘Did the prescribing doctor say what problem(s) s/he thought you had that
would be helped by taking antidepressants?’
Male 425 23.4 No 253 14.1
Female 1397 76.6 Yes 1538 85.9
Age ‘Could you estimate approximately how long the doctor spent with you on
the day they prescribed antidepressants?’
35 and under 690 37.8 15 min or less 758 41.9
36–55 846 46.4 15–30 min 607 33.6
Over 55 289 15.8 Over 30 min 443 24.5
Annual personal income ‘How would you describe your relationship with the doctor?’
Under $20 000 534 29.5 Not good/Not at all good 137 7.6
$20 000–60 000 737 40.7 Not sure 296 16.3
Over $60 000 541 29.9 Very good/Good 1379 76.1
Educational level ‘How well do you think your doctor understood your problem(s)?’
Not finished high school 129 7.1 Not a lot/Not at all 323 17.9
Finished high school 314 17.2 OK 387 21.4
Certificate/diploma 477 26.1 A lot/Quite a lot 1099 60.8
University degree 545 29.8
University postgrad degree 362 19.8
‘Please rate your level of depression in the year before taking antidepressants’ No of social causes indicated
Mild/none 333 19.4 >5 499 29.8
Moderate 649 37.8 3–5 771 46.1
Severe 733 42.7 <3 402 24.0
‘Who first suggested the idea of taking an antidepressant?’ No of biological causes identified
GP/Psychiatrist 1343 79.4 None/one 816 49.8
Informal (patient, relative, friend) 349 20.6 Two/three 823 50.2
‘In the 2 months before you were first prescribed antidepressants, had a loved
one died?’
Adverse effect severity score
No 1683 92.7 Score >20 291 26.1
Yes 133 7.3 Score 11–20 330 29.6
Score 0–10 495 44.4
‘Were you told what benefits to expect from taking the antidepressants?’ ‘Antidepressants are the best treatment’
No 395 22.2 Disagree/strongly disagree 654 39.4
Yes 1386 77.8 Not sure 675 40.7
Agree/strongly agree 331 19.9
‘Did the prescribing doctor tell you how antidepressants work?’ ‘If you benefitted from antidepressants, to what extent do you think it was
because of the chemical effect of the antidepressants vs. the placebo
effects of hope and expectation?’
No 731 41.3 >50% placebo 77 5.2
Yes 1039 58.7 50% chemical/50% placebo 195 13.2
>50% chemical 1203 81.6
‘Did the doctor tell you how long you should take the antidepressants for?’
No 807 45.1
Yes 982 54.9
‘Did the doctor inform you about possible side-effects?’
No 630 35.8
Yes 1130 64.2
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‘placebo’ eﬀects. Two additional factors, adverse
drug eﬀects reported by the participants and level
of depression in the year prior to prescription, were
also included in the analyses, because it was
assumed that they might also be predictors of per-
ceived eﬃcacy and, therefore, potential confound-
ers of relationships between the psychosocial
variables and the two outcome measures.
In the univariate analyses for the two outcomes,
the chi-squared test and the Cochran–Armitage
test-for-trend were used to estimate the statistical
signiﬁcance of association between each of the
potential explanatory variables and the two out-
come measures.
For both reduction in depression and improve-
ment in QoL, logistic regression models were con-
structed to estimate independent eﬀects associated
with positive outcome. The improvement in QoL
measure was rendered dichotomous by counting
‘greatly improved’ and ‘slightly improved’ as a
positive response and ‘unchanged’, ‘slightly worse’
and ‘a lot worse’ as a negative response. Only vari-
ables signiﬁcantly associated with outcome at the
univariate level for each of the two outcome mea-
sures were entered as covariates in the regression
models. For each covariate, Odds Ratios, 95%
Conﬁdence Intervals and the P-value are reported.
To optimise the eﬃciency of the two multivari-
ate analyses, the number of independent variables
was reduced by computing ‘scores’ based on an
aggregation of responses to related questionnaire
items or by transforming multiple items into a sin-
gle variable (see Tables 2 and 3).
A ‘social causes’ variable was created on the
basis of a respondent agreeing with a number of
potential causes of their depression that were social
or personal in nature. There were 10 of these
potential causes included in the questionnaire:
‘work stress’, ‘family stress’, ‘childhood neglect or
abuse’, ‘other distressing childhood experience’,
‘loss of loved one’, ‘pace of modern life’, ‘ﬁnancial
problems’, ‘relationship problems’, ‘social isola-
tion’ and ‘unemployment’. In the same section of
the questionnaire, three biological causes were
included as options: ‘heredity/genes’, ‘chemical
imbalance’ and ‘disorder of the brain’.
An adverse eﬀects score was computed using 20
side-eﬀects known to be potentially associated
with AD use, which were included as a list in the
questionnaire. Respondents were asked to rate
their experience of each, from ‘not at all’ (=0) to
‘severe’ (=3). An overall severity score was com-
puted for each respondent by aggregating
responses to the 20 items, to give a maximum
severity score of 60. The adverse eﬀects experi-
enced have been published in detail elsewhere
(13).
The ﬁve items relating to information provided
to the patient at the outset of AD use (pertaining
to expected beneﬁts of taking AD, how the AD
works, an estimate of duration, potential side-
eﬀects and the nature of the problem being
addressed by the AD) were collapsed into one
overall dichotomous measure of whether the
respondent reported they had received all this
information or not.
Finally, the two items requesting the respondent
to describe their relationship with the prescribing
doctor and to report how well s/he had understood
the patient’s problem were collapsed into one
dichotomous variable: Whether the respondent felt
that their relationship with the doctor was both
‘good’ (or ‘very good’) and that their problem was
understood ‘a lot’ (or ‘quite a lot’).
For both univariate and multivariate analyses,
a conventional criterion of statistical signiﬁcance
(P < 0.05) was assumed. SPSS (IBM, Armonk,
NY, USA) was used for analyses.
Results
Sample characteristics and descriptive data
Females constituted 76.6% of the sample. The
modal age group was 36–45 (24.2%); 16.3% were
18–25, and 15.9% were 56 or older. The men were
signiﬁcantly older than the women (P < 0.001). A
large majority, 92.1%, identiﬁed as ‘New Zealand/
European’; 2.9% as Maori, 1.2% as Asian, 0.4%
as Paciﬁc Islander and 3.5% as ‘Other’. The major-
ity, 89.1%, identiﬁed as heterosexual; 2.2% as gay,
2.9% as lesbian and 5.7% as bisexual. (Neither
ethnicity nor sexual orientation were included in
analyses, because of the low numbers in the smaller
groups).
In terms of education, 49.6% had a university
degree; 26.1% had gained a diploma or certiﬁcate
after high school, 17.2% had completed high
school, and 7.1% had not completed high school.
(In 2006, 14.2% of adult New Zealanders had an
undergraduate degree or higher and 22.4 per cent
had no formal qualiﬁcation (14)]. Education was
not signiﬁcantly related to age or gender. Annual
personal income (in New Zealand dollars) ranged
from ‘less than $10 000’ (15.0%) to ‘more than
$100 000’ (7.7%). The modal income was ‘$40 000
to $59 999’ (22.1%). [The median income of the
NZ population in 2012 was $29 000 (15)]. Income
was signiﬁcantly related to older age and being
male.
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About half (52.6%) reported ﬁrst being pre-
scribed ADs between 2000 and 2009; with 25.9%
reporting 2010–2013; 16.1% 1990–1999, and 5.4%
prior to 1990; and 69.1% were still taking ADs.
Just over half (51.7%) had taken them for more
than 3 years, and 7.8% for less than 3 months. In
83.6% of cases, the prescriber was a GP, and in
16.4% a psychiatrist. Of the 1715 (93.8%) who
Table 2. Variables associated with perceived reduction in depression
% (n/N) P Adjusted* Odds Ratio(95% CI) P
Gender
Male 78.4 (313/399) 0.009 1.0
Female 84.1 (1095/1302) 1.41 (0.64–3.09) 0.39
Age
Over 55 84.1 (228/271) 0.03 1.0
36–55 84.8 (668/788) 3.18 (1.03–9.83) 0.04
35 and under 79.8 (517/648) 4.16 (1.24–13.9) 0.02
Annual personal income
Under $20 000 75.8 (382/504) <0.001 1.0
$20 000–60 000 83.6 (572/684) 2.01 (0.96–4.21) 0.06
Over $60 000 88.5 (448/506) 5.56 (1.86–16.6) 0.002
Educational level
Not finished high school 76.1 (89/117) 0.003 1.0
Finished high school 77.6 (229/295) 0.39 (0.09–1.72) 0.21
Certificate/diploma 82.1 (368/448) 0.70 (0.17–2.97) 0.63
University degree 85.0 (431/507) 0.78 (0.19–3.16) 0.72
University postgrad degree 87.4 (298/341) 1.33 (0.27–6.62) 0.73
Loss in 2 months before antidepressants (AD) use
No 83.4 (1316/1578) 0.04 1.0
Yes 76.2 (93/122) 0.32 (0.11–0.88) 0.03
Received all key information† from doctor about AD
No 78.4 (845/1078) <0.001 1.0
Yes 91.3 (431/472) 2.73 (1.02–7.72) 0.04
Relationship with doctor ‘good’ and felt he/she understood the problem
No 69.8 (474/679) <0.001 1.0
Yes 91.6 (918/1002) 2.11 (1.01–4.49) 0.04
Time spent with doctor
15 min or less 76.4 (528/691) <0.001 1.0
15–30 min 86.5 (501/579) 0.82 (0.36–1.85) 0.63
Over 30 min 88.1 (370/420) 1.88 (0.70–5.07) 0.21
Who first suggested AD use
GP/Psychiatrist 81.5 (1023/1255) 0.002 1.0
Informal (patient, relative, friend) 88.6 (288/325) 1.37 (0.63–3.02) 0.43
Depression severity in year before AD use
Mild/none 66.5 (216/325) <0.001 1.0
Moderate 86.0 (551/641) 1.70 (0.73–3.91) 0.22
Severe 87.7 (641/731) 2.69 (1.13–6.39) 0.02
No of social causes indicated
>5 77.4 (384/496) <0.001 1.0
3–5 85.3 (654/762) 2.32 (1.12–4.80) 0.02
<3 86.3 (340/394) 4.19 (1.40–12.6) 0.01
No of biological causes indicated
None/one 79.6 (641/805) <0.001 1.0
Two/three 88.9 (724/814) 2.03 (0.99–4.16) 0.05
‘Antidepressants are the best treatment’
Disagree/strongly disagree 90.7 (606/668) <0.001 1.0
Not sure 70.0 (452/646) 1.76 (0.60–5.14) 0.30
Agree/strongly agree 95.1 (310/326) 1.93 (0.89–4.20) 0.10
Adverse effect severity score
Score >20 61.9 (180/291) <0.001 1.0
Score 11–20 86.2 (281/326) 3.09 (1.35–7.07) 0.008
Score 0–10 92.2 (450/488) 4.78 (2.02–11.3) <0.001
Chemical/placebo belief
>50% placebo 61.0 (47/77) <0.001 1.0
50% chemical/50% placebo 89.2 (174/195) 4.28 (1.41–13.1) 0.01
>50% chemical 94.8 (1125/1187) 6.88 (2.57–18.4) <0.001
*Adjusted for covariates that were significant in the univariate analysis.
†Information relating to expected benefits of taking AD, how the AD works, an estimate of duration, potential side-effects and the nature of the problem being addressed by the
AD.
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reported which AD they had been prescribed, the
most common was ﬂuoxetine (22.4%), followed by
citalopram (20.3%), paroxetine (8.7%), tricyclics
(4.5%) and venlafaxine (2.2%). Thirty-nine per-
cent reported that they had been prescribed multi-
ple ADs. Participants reported the following levels
Table 3. Variables associated with perceived improvement in quality of life
% (n/N) P Adjusted* Odds Ratio(95% CI) P
Gender
Male 78.4 (313/399) <0.001 1.0
Female 87.5 (1147/1311) 1.70 (0.81–3.57) 0.16
Age
Over 55 86.9 (239/275) 0.002 1.0
36–55 87.9 (695/791) 2.64 (0.75–9.35) 0.13
35 and under 81.5 (529/649) 2.84 (0.83–9.71) 0.10
Annual personal income
Under $20 000 80.8 (407/504) <0.001 1.0
$20 000–60 000 85.1 (587/690) 1.02 (0.45–2.31) 0.97
Over $60 000 90.2 (458/508) 1.94 (0.68–5.55) 0.22
Educational level
Not finished high school 81.9 (95/116) 0.19 – –
Finished high school 82.9 (247/298) – –
Certificate/diploma 85.1 (383/450) – –
University degree 85.5 (435/509) – –
University postgrad degree 89.0 (306/344) – –
Loss in 2 months before antidepressants (AD) use
No 85.7 (1358/1584) 0.19 – –
Yes 81.5 (101/124) – –
Received all key information† from doctor about AD
No 81.9 (887/1083) <0.001 1.0
Yes 92.6 (439/474) 1.36 (0.51–3.67) 0.54
Relationship with doctor ‘good’ and felt he/she understood the problem
No 72.5 (494/681) <0.001 1.0
Yes 94.0 (948/1009) 2.93 (1.29–6.66) 0.01
Time spent with doctor
15 min or less 78.3 (545/696) <0.001 1.0
15–30 min 90.5 (523/578) 1.42 (0.55–3.68) 0.46
Over 30 min 89.6 (381/425) 2.04 (0.80–5.21) 0.14
Who first suggested AD use
GP/Psychiatrist 84.5 (1066/1261) 0.04 1.0
Informal (patient, relative, friend) 89.0 (292/328) 1.73 (0.78–3.79) 0.17
Depression severity in year before AD use
Mild/none 70.1 (232/331) <0.001 1.0
Moderate 88.1 (571/648) 1.26 (0.52–3.09) 0.61
Severe 90.1 (656/728) 2.06 (0.83–5.11) 0.12
No of social causes indicated
>5 80.5 (400/497) <0.001 1.0
3–5 88.4 (680/769) 1.38 (0.65–2.99) 0.40
<3 87.8 (347/395) 1.65 (0.58–4.73) 0.40
No of biological causes indicated
None/one 81.9 (663/810) <0.001 1.0
Two/three 90.6 (742/819) 1.51 (0.73–3.11) 0.27
‘Antidepressants are the best treatment’
Disagree/strongly disagree 73.1 (474/648) <0.001 1.0
Not sure 92.4 (620/671) 2.10 (0.70–6.31) 0.19
Agree/strongly agree 96.7 (319/330) 2.65 (1.17–6.03) 0.02
Adverse effect severity score
Score >20 73.1 (474/648) <0.001 1.0
Score 11–20 92.4 (620/671) 2.63 (1.21–5.73) 0.02
Score 0–10 96.7 (319/330) 12.1 (3.84–28.4) <0.001
Chemical/placebo belief
>50% placebo 70.7 (53/75) <0.001 1.0
50% chemical/50% placebo 88.7 (173/195) 2.49 (0.78–7.97) 0.12
>50% chemical 96.3 (1152/1196) 3.06 (1.10–8.53) 0.03
*Adjusted for covariates that were significant in the univariate analysis.
†Information relating to expected benefits of taking AD, how the AD works, an estimate of duration, potential side-effects and the nature of the problem being addressed by the
AD.
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of depression in the year before taking ADs:
‘severe’ – 42.7%, ‘moderate’ – 37.8%, ‘mild’ –
11.8% and ‘not at all’ – 7.6%.
Association between psychosocial variables and perceived
depression reduction
Nearly 83% (1416/1710) of respondents perceived
a reduction in their depression as a result of taking
ADs. Of those who experienced a reduction, 1.3%
thought this happened the same day, 1.6% the next
day, 13.0% within 2–7 days, 17.3% in the second
week, 23.0% in the third week, 13.6% in the fourth
week and 30.2% in the next month.
All variables analysed were associated with per-
ceived depression reduction at the univariate level
(see Table 2).
Demographics. Compared with male respondents,
a signiﬁcantly higher proportion of females per-
ceived a reduction in their depression (84% vs.
78%, P = 0.009). Older participants (over 35) were
more likely to report a positive outcome (85% vs.
80% of younger respondents, P = 0.01). Higher
personal income was associated with perceived
reduction in depression (86% of those with income
>$20 000 a year compared to 76% of respondents
with a lower annual income, P < 0.001). Higher
proportions of those with a university degree
reported reduction in depression (86%, compared
to 80% of those without one, P < 0.001).
Patient–prescriber interactions. People receiving
relevant information when prescribed ADs were
more likely to report depression reduction. Over
85% of those who were told about potential beneﬁts
of taking the medication reported subsequent
improvement in depression, compared with 73% of
those who received no such information (P < 0.001).
Similar diﬀerences were found for those receiving
information about how the AD works (88% vs.
74%, P < 0.001), how long they should take it (85%
vs. 79%, P < 0.001), possible side-eﬀects (88% vs.
72%, P < 0.001) and the problems for which the
ADs would be helpful (84% vs. 74%, P < 0.001).
The length of the initial consultation with the
doctor was associated with perceiving a reduction
in depression; 87% of respondents having a
>15 min consultation compared to 76% of those
with a shorter one (P < 0.001). Compared with
participants who reported that their relationship
with the doctor was ‘not good’ ‘not at all good’ or
were ‘not sure’, those reporting a ‘good’ or ‘very
good’ relationship had a higher rate of reduction
in depression (67% vs. 87%, P < 0.001). A higher
proportion of respondents who felt that the doctor
understood their problem ‘a lot’ or ‘quite a lot’
experienced a reduction in their depression (91%
vs. 69%, P < 0.001).
Beliefs. Fewer (77%) respondents identifying
more than ﬁve social causes reported a reduction
in depression than those indicating ﬁve or less
(86%) (P < 0.001). Conversely, 89% of respon-
dents indicating more than one biological cause
reported a reduction in depression, compared with
80% of those reporting only one or no biological
cause (P < 0.001).
A belief that ‘antidepressants are the best treat-
ment for depression’ increased the likelihood of
perceived depression reduction (95% of those who
agreed with the statement, compared with 81% of
those who disagreed or were ‘not sure’, P < 0.001).
Nearly 95% of respondents who believed the eﬀect
of ADs is over 50% ‘chemical’ in nature reported a
reduction in depression, compared with 61% of
those who believed it was largely ‘placebo’
(P < 0.001).
Other. People receiving initial advice to take ADs
from an informal source (e.g. friend or family)
were more likely to have a subsequent positive out-
come (89%, compared with 82% receiving such
advice from a GP or psychiatrist, P = 0.002).
Within the small group (133) of respondents
who reported ‘loss of a loved one’ in the 2 months
before ﬁrst receiving an AD, the proportion of
those reporting depression reduction was lower
(76%, compared with 83% of those with no such
bereavement, P = 0.04)
Besides the 18 psychosocial variables, a higher
proportion of respondents reporting that their
depression was ‘moderate or severe’ in the year
before the ﬁrst AD prescription went on to per-
ceive a reduction in their depression (87%, com-
pared with 66% of those reporting ‘no or mild
depression’, P < 0.001). Finally, a higher score on
the adverse eﬀects scale was negatively associated
with reported reduction in depression. Sixty-two
percent of respondents scoring over 20 on the scale
reported depression reduction during the period of
AD use, compared with 92% of those with a score
of 10 or under (P < 0.001).
Regression analysis. Of the 12 non-pharmacologi-
cal items entered as covariates in a logistic regres-
sion model to estimate their independent eﬀect on
perceived depression reduction, seven retained
their statistically signiﬁcant eﬀect in the multivari-
ate model (see Table 2).
Age was independently associated with depres-
sion reduction; but the direction of the association
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was the reverse of that found at univariate level.
Respondents aged 35 and under were more likely
to report depression reduction than those aged
over 55 (Odds Ratio 4.2; P = 0.02). Respondents
with a personal annual income over $60 000 were
more likely than those with an income under
$20 000 to report reduction in depression (OR 5.6;
P = 0.002).
Respondents who described their relationship
with the prescribing doctor as ‘good’ and felt s/he
understood their problems were more likely to
report depression reduction than other participants
(OR 2.1; P = 0.04). People who were given full
information about ADs were more likely to experi-
ence a reduction in depression than those who were
not (OR 2.7; P = 0.04).
Respondents who responded ‘yes’ to ‘In the two
months before you were ﬁrst prescribed antide-
pressants, had a loved one died?’ were less likely to
report depression reduction than those responding
‘no’ OR 0.3; P = 0.03).
Two belief variables were independently predic-
tive of depression reduction. Respondents who
believed that the eﬀect of the AD was over 50%
chemical were more likely to report depression
reduction than those who believed it was largely
placebo (OR 6.9; P < 0.001). Respondents who
identiﬁed less than three social causes were more
likely to report reduced depression than those who
identiﬁed more than ﬁve (OR 4.2; P = 0.01). [Peo-
ple who selected two or three of the three biologi-
cal causes were more likely to report reduced
depression than those who selected one or none,
but this was not quite statistically signiﬁcant (OR
2.0; P = 0.05)].
In addition, participants who rated their depres-
sion in the year before the AD prescription as
‘severe’ were more likely to perceive depression
reduction than those who rated it as ‘mild’ or as
‘not at all’ (OR 2.7; P = 0.02). In terms of adverse
drug eﬀects, compared with the reference category
(>20), respondents scoring ≤10 or less were more
likely to report depression reduction (OR 4.8;
P < 0.001).
Association between psychosocial variables and perceived
improvement in quality of life
Responses to the item ‘While taking antidepres-
sants my QoL was . . .’ were as follows: ‘greatly
improved’ 49.2%, ‘slightly improved 36.1%,
‘unchanged’ 5.4%, ‘slightly worse’ 4.4% and ‘a lot
worse’ 4.5%. Sixteen of the 18 psychosocial vari-
ables were signiﬁcantly associated with this out-
come at the univariate level (the exceptions being
education level and loss of a loved one).
Demographics. A signiﬁcantly higher proportion
of females perceived an improvement in QoL (88%
vs. 78% of males, P < 0.001). Compared with the
younger group, older respondents (>35) were more
likely to report improvement in QoL (88% vs.
82%, P = 0.002). A higher personal income was
associated with a positive outcome (87% of those
with income >$20 000 a year reporting a QoL
improvement, compared with 81% of respondents
with a lower annual income, P = 0.001).
Patient–prescriber interactions. Over 88% of those
who were told about potential beneﬁts of taking
ADs reported improvement in QoL, compared
with 76% of those who received no such informa-
tion (P < 0.001). Similar diﬀerences in reported
QoL improvement were found for those receiving
information about how the AD works (90% vs.
78%, P < 0.001), how long they should take it
(87% vs. 83%, P = 0.02), possible side-eﬀects
(90% vs. 76%, P < 0.001) and the problems that
the AD would treat (87% vs. 75%, P < 0.001).
The length of the initial consultation was associ-
ated with improved QoL [90% of respondents hav-
ing a >15 min consultation compared with 78% of
those with a shorter one (P < 0.001)]. Those
reporting a ‘good’ relationship with their doctor
had a higher rate of reporting QoL improvement
(90% vs. 69% of those rating relationship as ‘not
good’ or ‘not sure’, P < 0.001). A higher propor-
tion of respondents who felt that the doctor under-
stood their problem ‘a lot’ experienced an
improvement in their QoL (94% vs. 72%,
P < 0.001).
Beliefs. Respondents seeing social causes as the
basis of their depression were less likely to report
improvement in QoL Eighty-one percent of those
indicating more than ﬁve social causes in the sur-
vey reported QoL improvement, compared with
88% of those indicating ﬁve or less (P < 0.001).
Conversely, 91% of respondents who indicated
two or three biological causes reported an
improvement in QoL, compared with only 82% of
those reporting one or no biological cause
(P < 0.001).
When the respondent agreed that ‘antidepres-
sants are the best treatment for depression’, the
likelihood of a reported QoL improvement
increased (97% of those who agreed with the state-
ment compared to only 73% of those who dis-
agreed, P < 0.001). Nearly 96% of respondents
who believed that the eﬀect of the AD was ‘over
50% chemical’ reported a QoL improvement, com-
pared with 71% of those who believed it was lar-
gely placebo (P < 0.001).
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Other. People who had initially been advised to
take ADs from an informal source (e.g. friend or
family) were more likely to perceive QoL improve-
ment (89%, compared to 85% receiving such
advice from a GP or psychiatrist, P = 0.04).
Higher proportions of respondents reporting
that their depression was ‘moderate or severe’ in
the year before the ﬁrst AD prescription went on
to perceive some improvement in QoL (89%, com-
pared to 70% of those reporting ‘no or mild
depression’, P < 0.001).
A perceived improvement in QoL was more
likely for those respondents with lower adverse
eﬀect severity scores. Nearly 95% of those scoring
10 or under on the severity scale reported QoL
improvement, compared with only 71% of those
with a score higher than 20 (P < 0.001).
Regression analysis. Only three of the psychosocial
variables entered as covariates in the logistic
regression model for perceived improvement in
QoL retained their statistically signiﬁcant eﬀect in
the multivariate model (Table 3). (Two of these
were in common with the variables independently
predicting depression reduction: relationship with
doctor and belief in ‘chemical’ vs. ‘placebo’
eﬀects).
Respondents who described their relationship
with the prescribing doctor as ‘good’ and felt s/he
understood their problems were more likely to
report improved QoL (OR 2.9; P = 0.01). Com-
pared with respondents who believed that the eﬀect
of the AD was largely placebo, those who reported
that it was over 50% chemical were more likely to
report QoL improvement (OR 3.1; P = 0.03).
Unlike depression reduction, improved QoL was
related to believing that ‘antidepressants are the
best treatment’ (P = 0.02).
In terms of adverse eﬀects, compared with the
reference category (score of over 20), respondents
scoring 10 or less were more likely to report
improvement in QoL (OR 12.1; P < .001). Severity
of depression was not signiﬁcantly related to
improved QoL in the regression analysis.
Discussion
The overall pattern of results indicates that the
perceived eﬃcacy of ADs is strongly related to a
large range of psychosocial variables, including
age, income, beliefs and attitudes, and the relation-
ship with, and information imparted by, the pre-
scriber. Ten of these eﬀects (seven for depression
reduction and three for improved QoL) were inde-
pendent of each other and of self-reported adverse
eﬀects and depression severity. While some of
these relationships have been identiﬁed before,
others, such as the amount of information
imparted, and beliefs about placebo vs. chemical
eﬀects, have not.
Positive ﬁndings on the two outcome measures
can result from either the therapeutic eﬀect chemi-
cally induced by AD drugs or non-speciﬁc, non-
pharmacological eﬀects or both. Our ﬁndings,
therefore, are informative whether understood as
identifying which factors might be enhancing the
pharmacological eﬀects of ADs or seen from the
perspective of identifying purely non-pharmaco-
logical, psychosocial factors. Some psychosocial
variables, such as gender and age, may inﬂuence
the chemical eﬀects of ADs (see Demographics
below). It is harder to see how beliefs, about
causes, ADs and placebo eﬀects, or how well one
felt understood by the prescriber and how much
information was received, might enhance the
chemical eﬀects.
The prescriber–patient relationship
In psychotherapy research, including for depres-
sion (16), the therapeutic alliance is well estab-
lished as a strong predictor of positive outcome.
This is rarely assessed, however, in drug trials (7).
In the current study, the patient–prescriber rela-
tionship was a powerful, independent predictor of
the perceived eﬃcacy of ADs. Related factors,
such as the amount of information conveyed, were
also related to a positive outcome. The few studies
that have reported on interactions with patients in
the process of prescribing ADs tend to adopt a
rather narrow medical framework, assuming that
the relationship and information are important
primarily because they increase adherence to medi-
cation [which can be as low as 32% after 3 months
(17)], rather than because they can have a direct
eﬀect on depression (17–19). A recent study of 43
psychiatrists found that the consultations in which
ADs were prescribed lasted an average of
17.5 min, that the most commonly discussed topic
was ‘medication adherence’ and that in none of the
200 meetings was the patient ‘given an opportunity
to talk’ (20).
Beliefs and attitudes
Previous studies in the domain of patients’ beliefs
– for a range of treatments and problems – have
often, understandably, focussed on receiving one’s
preferred treatment (21) and having positive treat-
ment expectations (22), both of which, perhaps
unsurprisingly, are highly predictive of positive
outcome with ADs. In the current study, causal
442
Read et al.
beliefs and low belief in the placebo eﬀect were
related to perceived positive outcomes. It should
be noted, however, that assessing beliefs or
attitudes after a view on eﬃcacy has been formed
means that the former could have been deter-
mined by the latter, rather than vice versa. For
example, belief in biogenetic (vs. social) causes
and in chemical eﬀects (vs. placebo eﬀects) may
operate to enhance perceived eﬃcacy, but may
also be increased by a positive outcome, via either
pharmacological and/or non-pharmacological
eﬀects.
Demographics
The worse depression outcomes for poorer people
in the current study have been found fairly consis-
tently (23, 24), with some exceptions (21). The
most parsimonious explanation seems to be that
the adverse social factors which often precipitate
depression, and which are experienced more often
by poorer people, also inhibit the eﬀectiveness of
ADs because they do not disappear with an AD
prescription (23).
Future research might address diﬀerential
outcomes by gender and age, with a focus on mea-
suring both pharmacological and non-pharmaco-
logical eﬀects inﬂuencing any diﬀerences. For
example, in the current study, women were signiﬁ-
cantly more likely to report both depression reduc-
tion and improved QoL (although in the
regression analyses the odds ratios – 1.41 and 1.70
respectively – were not statistically signiﬁcant).
Possible biological explanations for gender diﬀer-
ences might include ovarian hormones, and meno-
pausal status (25) and body mass at same dosage
(which, along with metabolic rate diﬀerences,
might also partially explain diﬀerential response
by age). Possible psychosocial variables that could
potentially enhance perceived eﬃcacy in women
might include better therapeutic relationships.
Women in the current study reported a slightly
better relationship with the prescriber (1.96 vs.
1.85; P = 0.03), but there was no diﬀerence in how
understood they felt. Women were also more likely
to be told about the beneﬁts of ADs (79.0 vs.
73.7%; P = 0.02) and more likely to be told what
problems they had that would be helped (87.4%
vs. 80.8%; P = 0.001).
Clinical implications
This is by no means the ﬁrst study of ADs to sug-
gest that clinicians can inﬂuence treatment out-
comes via the nature of their interactions with
patients (26, 27). A recent systematic review of a
wide range of treatments for depression con-
cluded:
Although the surface features of psychotherapy, antide-
pressants, exercise and acupuncture are very diﬀerent,
they do result in similar reduction of depressive symp-
toms and may have the same mechanisms of action. The
lack of signiﬁcant diﬀerences between very diverse active
treatments suggests that non-speciﬁc therapeutic factors
may account for a large part of the eﬀectiveness of these
depression treatments (6, p. 9).
What are the ramiﬁcations of ﬁnding so many
psychological and social predictors of eﬀectiveness,
as experienced by AD recipients, in this and previ-
ous studies? Perhaps the most obvious clinical
implications, beyond trying to ameliorate the
social circumstances driving the depression – such
as poverty, emanate from the ﬁndings about the
relationship with the prescriber and the amount of
information provided (which no doubt helps build
the relationship). Rather than regarding placebo
or ‘non-speciﬁc’ eﬀects as merely an irritating
threat to eﬀorts to prove the eﬃcacy of one’s
favoured treatment, it can be useful to understand
them and then enhance them. Making the time
(which is not always easy) to explore the patient’s
view of their problems, including their thoughts
about ADs [which are often complex and ambiva-
lent (28)], and about alternative treatments, and
their causal beliefs (which may diﬀer from our
own) is also important. Another New Zealand
study found that GPs often do explore psychoso-
cial causes and consider non-medical treatments
but are constrained from making appropriate
referrals by the lack of accessible, aﬀordable ser-
vices (29).
The interpersonal factors in a professional
encounter in which a decision about ADs, or any
other treatment is being considered, may, for some
patients, be more important than the decision itself
or the treatment itself. Listening carefully to some-
one’s story, rather than being too concerned about
adherence to a single treatment modality, can, it
seems, be curative all by itself. Indeed, a recent
British Medical Journal review of issues relating to
diagnosis of, and treatment for, depression (3),
concluded:
High rates of placebo response account for much of the
seeming beneﬁcial eﬀects of medication and this should
be discussed sensitively with patients, who also need to
be made aware of the side-eﬀects, risks and costs associ-
ated with ADs. Informing them of the way that drug
companies have acted to boost sales of their drugs may
also be appropriate. There is still a widely held belief
that all depression is “brain disease” caused by chemical
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imbalance which can be “corrected” by pills, and
countering it is important by noting the relevance of life
circumstances.
This focus on social factors is consistent with a
recent call for the adoption of a public health
approach to the prevention and alleviation of
depression (30).
Limitations
This self-selected, convenience sample, despite
being the largest ever surveyed, was not, in some
regards, representative of the New Zealand popu-
lation. Maori, Paciﬁc Islanders, men, older people,
and poorer and less educated people were all
under-represented. The over-representation of
women (77%) is not of great concern because
women are prescribed ADs at approximately twice
the rate as men internationally. Although an inter-
net sample may be biased towards the more
wealthy and better educated, 80% of New Zealand
households have internet access. The use of the in-
ternet does, however, introduce the possibility that
people who are disgruntled with their treatment
may be over-represented. This seems unlikely,
however, given that the majority (83%) reported
that they believed the drugs had reduced their
depression, a rate far higher than most conven-
tional eﬃcacy studies of ADs.
The study relied on self-report. Conventional
studies, however, also rely, to varying degree, on
self-report. One concern is that some of the data
are retrospective and therefore subject to the falli-
bilities of memory of experiences from weeks to
several years in the past. The majority (69%), how-
ever, were still taking the ADs at the time of com-
pleting the questionnaire.
It is diﬃcult to draw ﬁrm conclusions about the
meaning of some of the ﬁndings, including about
causality, or the direction thereof. For example,
the relationship between positive attitudes to ADs
and positive outcome, if causal, could have been in
either direction, or both. Therefore, prospective
studies are essential.
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